The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer

(2010) J. Hofland et al.   CANCER RESEARCH

Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

(2010) T. Puchalski et al.   CLINICAL CANCER RESEARCH

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

(2010) T. B. Dorff et al.   CLINICAL CANCER RESEARCH

Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models

(2009) M. G. Cornejo et al.   BLOOD

Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells

(2009) J. Y. Chun et al.   CLINICAL CANCER RESEARCH

Vitamin D May Reduce Prostate Cancer Metastasis by Several Mechanisms Including Blocking Stat3

(2008) William B. Grant   AMERICAN JOURNAL OF PATHOLOGY

Stat3 Promotes Metastatic Progression of Prostate Cancer

(2008) Junaid Abdulghani et al.   AMERICAN JOURNAL OF PATHOLOGY

Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men

(2008) T. A. Wallace et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

A novel role of Shc adaptor proteins in steroid hormone-regulated cancers

(2008) Syed Mahfuzul Alam et al.   ENDOCRINE-RELATED CANCER

Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor

(2008) Kamilla Malinowska et al.   ENDOCRINE-RELATED CANCER

Grb2 signaling in cell motility and cancer

(2008) Alessio Giubellino et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

17β-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer

(2008) Joanna M. Day et al.   INTERNATIONAL JOURNAL OF CANCER